• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BEO
Click for more information
6.67% 2.8¢

BEONIC LTD - News & Media

Market Cap $17.64M  ! watchlist Created with Sketch. Add to my watchlist
Technology Software - Application

Beonic Ltd, formerly Skyfii Limited, is an Australia-based company. It offers an... Beonic Ltd, formerly Skyfii Limited, is an Australia-based company. It offers an artificial intelligence (AI) platform, Beonic for places. Its technology creates intelligent places that adapt to the needs of people and provides venues with insights into their operations and visitor behaviors. Through the combination of Internet of Things (IoT) and AI, it helps its customers understand how visitors interact with their spaces, working as their partner to create transformative experiences that enable places to adapt and respond to the demand of their people. The three core modules of the Beonic platform include Connect, Insight, and Engage. It provides solutions, such as Occupancy & People Counting, Queue Management, and Guest Wifi & Marketing. Its People Counting Technology captures accurate footfall data in real time, providing key insights into visitor behavior. Its queue management solution visualizes queues, keeps visitors informed, and optimizes staff levels to reduce wait times.More

No News & Media currently available.

(20min delay)
Last
2.8¢ 		Change
-0.002(6.67%) 		Mkt cap ! $17.64M
Open High Low Value Volume
2.8¢ 2.8¢ 2.8¢ $560 20K

Buyers (Bids)

No. Vol. Price($)
1 62750 2.5¢
 

Sellers (Offers)

Price($) Vol. No.
2.8¢ 75636 1
View Market Depth
Last trade - 10.45am 02/10/2024 (20 minute delay) ?
BEO (ASX) Chart

Top Stories

PainChek close to finding out if FDA approves its flagship app for use in dementia care

PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t Maximus Resources (ASX:MXR) has unveiled its latest drilling assay results at Eagles Nest, hitting gold downhole multiple assets.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.